Cubist Touts Activity Of Its Broad-Spectrum Antibiotic Candidate Against High Value Gram-Negative Targets
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Cubist Pharmaceuticals laid out the regulatory plan for its novel broad-spectrum cephalosporin/tazobactam combination antibiotic CXA-201 during an R&D day Sept. 20, disclosing plans to go ahead with development of the drug in hospital-acquired and ventilator-associated pneumonia
You may also be interested in...
Novel Antibiotics At ICAAC Spur Optimism On Resistance Front
While short-term prospects are dim for new antibiotics to treat multi-drug-resistant pathogens – Gram-negative bacteria in particular – research presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy indicates a handful of novel compounds could be ready for prime time in as few as four or five years.
Novel Antibiotics At ICAAC Spur Optimism On Resistance Front
While short-term prospects are dim for new antibiotics to treat multi-drug-resistant pathogens – Gram-negative bacteria in particular – research presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy indicates a handful of novel compounds could be ready for prime time in as few as four or five years.
Antibiotic Development: Where Wall Street Guidance Is Watching FDA Guidances
FDA's effort to create a clearer path for antibiotic development has produced a series of new guidance documents. Those guidances are making some products in development look well-positioned for regulatory review, and rekindling the interest on Wall Street in specialty antibiotic firms. This article first appeared in the May 2011 issue of The RPM Report.